Commerce Bank Has $6,877,000 Stake in Eli Lilly and Co. (LLY)
Commerce Bank cut its stake in Eli Lilly and Co. (NYSE:LLY) by 0.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 85,691 shares of the company’s stock after selling 665 shares during the period. Commerce Bank’s holdings in Eli Lilly and were worth $6,877,000 at the end of the most recent quarter.
Other large investors also recently bought and sold shares of the company. Iowa State Bank bought a new stake in Eli Lilly and during the second quarter valued at $104,000. PineBridge Investments L.P. raised its stake in Eli Lilly and by 208.6% in the second quarter. PineBridge Investments L.P. now owns 1,361 shares of the company’s stock valued at $108,000 after buying an additional 920 shares during the period. Integrated Wealth Management raised its stake in Eli Lilly and by 3.7% in the third quarter. Integrated Wealth Management now owns 1,389 shares of the company’s stock valued at $112,000 after buying an additional 50 shares during the period. Financial Architects Inc raised its stake in Eli Lilly and by 4.5% in the third quarter. Financial Architects Inc now owns 1,423 shares of the company’s stock valued at $114,000 after buying an additional 61 shares during the period. Finally, Cribstone Capital Management LLC bought a new stake in Eli Lilly and during the second quarter valued at $117,000. Hedge funds and other institutional investors own 73.93% of the company’s stock.
Shares of Eli Lilly and Co. (NYSE:LLY) traded down 2.78% during trading on Monday, hitting $67.20. The stock had a trading volume of 12,456,692 shares. Eli Lilly and Co. has a one year low of $64.18 and a one year high of $88.16. The stock has a market capitalization of $71.08 billion, a price-to-earnings ratio of 29.23 and a beta of 0.28. The stock has a 50 day moving average price of $76.69 and a 200-day moving average price of $77.92.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Tuesday, October 25th. The company reported $0.88 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.96 by $0.08. The firm had revenue of $5.19 billion for the quarter, compared to analyst estimates of $4.23 billion. Eli Lilly and had a return on equity of 23.71% and a net margin of 11.73%. The business’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same period in the previous year, the business posted $0.89 earnings per share. On average, equities research analysts predict that Eli Lilly and Co. will post $3.55 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, December 9th. Investors of record on Tuesday, November 15th will be issued a dividend of $0.51 per share. The ex-dividend date of this dividend is Thursday, November 10th. This represents a $2.04 annualized dividend and a yield of 2.95%. Eli Lilly and’s payout ratio is currently 88.70%.
ILLEGAL ACTIVITY WARNING: This piece was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US and international trademark and copyright laws. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2016/11/28/commerce-bank-has-6877000-stake-in-eli-lilly-and-co-lly.html.
Several equities research analysts recently weighed in on LLY shares. BMO Capital Markets restated a “buy” rating and issued a $94.00 target price on shares of Eli Lilly and in a report on Monday, October 3rd. Zacks Investment Research upgraded Eli Lilly and from a “hold” rating to a “buy” rating and set a $89.00 price target for the company in a report on Tuesday, September 27th. Goldman Sachs Group Inc. upgraded Eli Lilly and from a “neutral” rating to a “buy” rating and upped their price target for the stock from $89.00 to $95.00 in a report on Tuesday, September 27th. Deutsche Bank AG reiterated a “buy” rating on shares of Eli Lilly and in a report on Tuesday, September 20th. Finally, Jefferies Group reiterated a “buy” rating and set a $105.00 price target on shares of Eli Lilly and in a report on Wednesday, September 14th. Four research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $108.34.
In other Eli Lilly and news, insider Maria A. Crowe sold 2,248 shares of Eli Lilly and stock in a transaction on Wednesday, October 5th. The stock was sold at an average price of $81.37, for a total value of $182,919.76. Following the completion of the transaction, the insider now directly owns 94,319 shares of the company’s stock, valued at approximately $7,674,737.03. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.20% of the company’s stock.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Stock Ratings for Eli Lilly and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co. and related stocks with our FREE daily email newsletter.